DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
| Autor: | Adi Lahat, Ágnes Salamon, Chang-Soo Eun, Andrey E. Dorofeyev, Jae Hee Cheon, O. Levchenko, M. Pesegova, Sigal Fishman, Yoon-Goo Kim, O. Alexeeva, Byong Duk Ye, S.Y. Lee, Radu Bogdan Mateescu, S J Lee, Maria Lia Scribano, M. Osipenko, Kang-Moon Lee |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Crohn's disease
medicine.medical_specialty Randomization business.industry Gastroenterology Biosimilar Azathioprine General Medicine medicine.disease Crohn's Disease Activity Index Infliximab law.invention 03 medical and health sciences 0302 clinical medicine Biosimilar Pharmaceuticals Randomized controlled trial law 030220 oncology & carcinogenesis Internal medicine medicine Physical therapy 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 11:S62-S62 |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjx002.098 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|